CIM
IOVA icon

CIM Investment Management’s Iovance Biotherapeutics IOVA Stock Holding History

CIM Investment Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-29,423
Closed -$80.3K – 258
2025
Q4 		$80.3K Hold
29,423
– – 0.02% 238
2025
Q3 		$63.8K Sell
29,423
-31,694
-52% -$74.8K 0.02% 243
2025
Q2 		$282K Buy
61,117
+30,671
+101% +$76.3K 0.05% 217
2025
Q1 		$101K Sell
30,446
-726
-2% -$3.74K 0.02% 230
2024
Q4 		$231K Hold
31,172
– – 0.07% 214
2024
Q3 		$293K Hold
31,172
– – 0.09% 190
2024
Q2 		$250K Buy
31,172
+17,399
+126% +$186K 0.08% 200
2024
Q1 		$204K Hold
13,773
– – 0.06% 255
2023
Q4 		$112K Hold
13,773
– – 0.04% 277
2023
Q3 		$62.7K Hold
13,773
– – 0.02% 273
2023
Q2 		$97K Hold
13,773
– – 0.03% 269
2023
Q1 		$84.2K Buy
13,773
+476
+4% +$3.28K 0.03% 257
2022
Q4 		$85K Buy
+13,297
New +$104K 0.03% 237

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

CIM Investment Management's IOVA Position: Q1 2026 in Review

CIM Investment Management sold out of Iovance Biotherapeutics (IOVA) in Q1 2026, closing a stake of 29,423 shares — an estimated $80.3K sold.

CIM Investment Management first reported a position in IOVA in Q4 2022 and held it in 13 quarters. The position peaked at $293K in Q3 2024. 286 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • CIM Investment Management reported no remaining Iovance Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • CIM Investment Management sold 29,423 Iovance Biotherapeutics shares in Q1 2026, an estimated $80.3K.
  • CIM Investment Management first reported a position in Iovance Biotherapeutics in Q4 2022 and held it in 13 quarters.
  • CIM Investment Management's Iovance Biotherapeutics position peaked at $293K in Q3 2024.
  • 286 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on CIM Investment Management's 13F filing for Q1 2026, filed 19 May 2026.